Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs ResMed Inc. — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.82, while ResMed Inc. trades at $197.6 (market cap $28.00B). The key difference: ResMed Inc. pays a 1.24% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Bitwise Crypto Industry Innovators ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| BITQ | RMD | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $293.73 |
52-Week Low | $16.74 | $182.82 |
Market Cap | — | $28.00B |
Enterprise Value | — | $27.18B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.
The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
